Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-adjuvant Pembrolizumab for MMRd Uterine Cancer
NCT06180733Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2023
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in endometrial cancer (EC), sponsored by University Medical Center Groningen. Started Dec 2023; status: active, not recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06180733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06180733.